Related Experiment Videos
8-Cl-cAMP antagonizes mitogen-activated protein kinase activation and cell growth stimulation induced by epidermal
A Budillon1, E Di Gennaro, M Caraglia
1Istituto Nazionale dei Tumori, Fondazione G Pascale, Napoli, Italy.
Abstract:
The growth factor-activated mitogenic pathways are often disregulated in tumour cells and, therefore, they can provide specific molecular targets for novel anti-tumour approaches. 8-Chloro-cAMP (8-Cl-cAMP), a synthetic cAMP analogue, is a novel anti-tumour agent that has recently undergone clinical evaluation. We investigated the effects of 8-Cl-cAMP on the epidermal growth factor (EGF)/EGF receptor (EGF-R) signalling in human epidermoid cancer KB cells, which are responsive to the mitogenic stimulus of EGF. We found that the growth-promoting activity of EGF was completely abolished when EGF treatment was performed in combination with 8-Cl-cAMP. The inhibition of the EGF-induced proliferation by 8-Cl-cAMP was paralleled by the blockade of the EGF-stimulated activation of mitogen-activated protein kinases (MAPK), ERK-1 and ERK-2. Conversely, we found an increase of EGF-R expression and EGF-R tyrosine phosphorylation when KB cells were growth inhibited by 8-Cl-cAMP. Moreover, the activity of Raf-1 and MEK-1 protein kinases, the activators upstream MAPK in the phosphorylation cascade induced by EGF, was not modified in 8-Cl-cAMP-treated cells. We concluded that the impairment of KB cell response to EGF, induced by 8-Cl-cAMP, resides in the specific inhibition of MAPK/ERKs activity while the function of the upstream elements in the EGF-R signalling is preserved.
Insights
8-Chloro-cAMP (8-Cl-cAMP) inhibits epidermal growth factor (EGF)-induced cancer cell proliferation by blocking mitogen-activated protein kinases (MAPK)/ERK activity. This novel anti-tumor agent preserves upstream EGF receptor signaling, offering a targeted approach for cancer therapy.
Area of Science:
- Oncology
- Molecular Biology
- Cell Signaling
Background:
- Disregulated growth factor-activated mitogenic pathways are common in tumor cells, presenting molecular targets for anti-cancer therapies.
- 8-Chloro-cAMP (8-Cl-cAMP), a synthetic cAMP analogue, is an emerging anti-tumor agent with recent clinical evaluation.
Purpose of the Study:
- To investigate the effects of 8-Cl-cAMP on epidermal growth factor (EGF)/EGF receptor (EGF-R) signaling in human epidermoid cancer KB cells.
- To elucidate the specific molecular mechanisms by which 8-Cl-cAMP inhibits EGF-induced proliferation.
Main Methods:
- KB cells were treated with EGF alone or in combination with 8-Cl-cAMP.
- Analysis of EGF-induced proliferation, EGF-R expression, tyrosine phosphorylation, and the activity of MAPK/ERK, Raf-1, and MEK-1 kinases.
Main Results:
- 8-Cl-cAMP completely abolished EGF-induced proliferation and blocked EGF-stimulated activation of MAPK (ERK-1 and ERK-2).
- EGF-R expression and tyrosine phosphorylation increased in KB cells growth-inhibited by 8-Cl-cAMP.
- Activity of upstream kinases Raf-1 and MEK-1 remained unaffected by 8-Cl-cAMP treatment.
Conclusions:
- 8-Cl-cAMP impairs KB cell response to EGF by specifically inhibiting MAPK/ERK activity.
- The upstream components of the EGF-R signaling pathway remain functional, suggesting a targeted mechanism of action for 8-Cl-cAMP.